Jon Congleton, Mineralys
Mineralys emerges with a new take on an old idea for the treatment of hypertension and $40M to play with
Aldosterone, a hormone linked to increased blood pressure, has long been a target of interest for the treatment of hypertension, but selectivity has been a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.